The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for nintedanib (Boehringer Ingelheim Pty Ltd)
Active ingredients
nintedanib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Capsule, soft
Indication
Nintedanib is indicated for the treatment of Systemic Sclerosis (SSc)
Therapeutic area
Immunology